Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Disease/ Diagnostics

show results
Refine your search

Search term:

Results 1 - 10 of 1467 > >>
EC Number Disease PubMed ID Title of Publication Category Confidence Level
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Breast Neoplasms 29751678 (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. causal interaction
therapeutic application
unassigned
1
1
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Carcinoma 29751678 (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. causal interaction
therapeutic application
unassigned
1
1
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Triple Negative Breast Neoplasms 29751678 (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. causal interaction
therapeutic application
unassigned
1
1
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Neoplasms 27343380 (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation. causal interaction
unassigned
3
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Breast Neoplasms 27291048 1, 3, 6-Trihydroxy-7-methyl-9, 10-anthracenedione isolated from genus Lindera with anti-cancer activity. causal interaction
ongoing research
therapeutic application
unassigned
3
2
4
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Neoplasms 27291048 1, 3, 6-Trihydroxy-7-methyl-9, 10-anthracenedione isolated from genus Lindera with anti-cancer activity. causal interaction
ongoing research
therapeutic application
unassigned
3
2
4
0
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Carcinoma 18199615 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
4
4
2
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Neoplasms 18199615 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
4
4
2
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Prostatic Neoplasms 18199615 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
4
4
2
Show all pathways known for 2.3.1.39Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.39Neuroblastoma 20053345 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. ongoing research
unassigned
1
0
Results 1 - 10 of 1467 > >>